

July 10, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

To,
The Manager – Listing
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform you that the Board of Directors, at its meeting held today on July 10, 2024, approved the sale of up to 96,09,571 equity shares of Glenmark Life Sciences Limited (“GLS”) representing 7.84% of the issued and paid-up equity share capital of GLS, held by the Company (including equity shares held by certain individuals where the beneficial ownership is with the Company), by way of an offer for sale through the stock exchange mechanism, in accordance with the applicable law.

This is for your information and records.

For and on behalf of **Glenmark Pharmaceuticals Limited**

Harish Kuber
Company Secretary and Compliance Officer
Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)